Every 8-K that Boston Scientific Corporation (BSX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BSX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BSX filings page.
Boston Scientific Corporation (BSX) reports a material cybersecurity incident that caused a global disruption of its information technology systems, temporarily affecting manufacturing and the processing and shipment of customer orders. The company has substantially restored its distribution network, resumed sterilization operations, and restarted manufacturing at most facilities worldwide.
Based on current information, Boston Scientific expects the incident to have a material impact on results for the third quarter and full year 2026 and believes it is unlikely to meet its previously issued net sales growth and adjusted EPS guidance for those periods. The company plans to update its 2026 outlook on October 28, 2026, and does not currently expect a material impact on its long-term financial condition.
BOSTON SCIENTIFIC CORP (BSX) reported that on August 25, 2026 it identified a cybersecurity incident affecting certain information technology systems, resulting in a global disruption to its operations. The company activated incident response protocols and engaged third-party cybersecurity experts to investigate and contain the threat.
The incident has caused, and is expected to continue to cause, disruptions and limitations of access to information systems and business applications that support operations, including the ability to process and ship customer orders. Boston Scientific is working to restore affected functions, but the timeline for full restoration is not yet known.
The company states that its investigation is ongoing and that the full scope, nature and impacts, including operational and financial effects, are not yet known. It has not yet determined whether the incident is reasonably likely to have a material impact on the company, and highlights risks such as potential litigation, reputational risk, regulatory scrutiny and possible adverse impacts on business, results of operations or financial condition.
Boston Scientific Corporation reported strong results for the quarter ended June 30, 2026, with net sales of $5.442 billion, up 7.5 percent on a reported basis and 7.0 percent on an operational and organic basis versus a year earlier. GAAP net income attributable to common stockholders was $907 million, or $0.61 per diluted share, compared with $797 million, or $0.53 per share. Adjusted EPS was $0.86, up from $0.75 and above the company’s guidance range of $0.82 to $0.84.
MedSurg net sales were $1.818 billion, up 5.9 percent reported, while Cardiovascular reached $3.624 billion, up 8.3 percent. Regional growth was 6.2 percent in the U.S., 11.2 percent in Asia-Pacific and 22.4 percent in Latin America and Canada on a reported basis.
The company completed a $2 billion accelerated share repurchase program, buying approximately 40 million shares, and invested $1.5 billion for an approximately 34 percent stake in MiRus LLC with an exclusive option on its TAVR business. For 2026, it projects reported net sales growth of 5.5 to 6.5 percent and adjusted EPS of $3.28 to $3.32, with third-quarter adjusted EPS expected at $0.80 to $0.82.
Boston Scientific Corporation approved a new global restructuring program, the 2026 Restructuring Plan, on July 21, 2026. The plan is intended to drive sustained cost efficiencies and support growth by optimizing the supply chain, transferring certain production lines among facilities, and reshaping functional and organizational structures.
The program is expected to be initiated in 2026 and substantially completed by the end of 2029. Boston Scientific estimates total pre-tax charges of $700 million to $800 million, including $300 million to $350 million of transfer costs, $275 million to $300 million of termination benefits, and $125 million to $150 million of other costs such as consulting, contractual cancellations, program management, accelerated depreciation and fixed asset write-offs. Of the total charges, $600 million to $700 million are expected to result in future cash outlays.
The company expects the plan to reduce gross annual pre-tax expenses by approximately $500 million as benefits are realized, with a substantial portion of these savings to be reinvested in strategic growth initiatives. While new roles will be created in growth areas, the company does expect some headcount reductions as a result of the restructuring.
Boston Scientific Corporation has entered into a $2 billion accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank as part of its previously announced $5 billion share repurchase authorization. The company will initially receive shares equal to 80% of the repurchase price, or about 30.4 million shares, based on the May 15, 2026 closing price of $52.68 per share. The final number of shares will be set using the volume‑weighted average price of the stock during the ASR term, less a discount, with settlement expected by June 30, 2026. After this transaction, $3 billion will remain available under the authorization, and management expects the ASR to add $0.02 to adjusted earnings per share for full‑year 2026 versus prior guidance.
Boston Scientific Corporation has made a major strategic investment in MiRus LLC, a private developer of cardiovascular and orthopedic technologies, including the SIEGEL transcatheter aortic valve replacement (TAVR) system. The company paid $1.5 billion in cash for non-voting equity and an exclusive option on the TAVR business.
The investment gives Boston Scientific 33.75% of MiRus on a fully diluted basis and a Call Option to acquire 100% of a new MiRus subsidiary holding the TAVR assets for additional aggregate cash payments totaling $3.0 billion, contingent on clinical and regulatory milestones. MiRus may also receive future sales-based payments if the option is exercised.
The SIEGEL TAVR valve uses a proprietary nickel-free rhenium alloy, dry porcine tissue leaflets and an 8 French delivery system designed to reduce vascular complications. MiRus has begun the STAR pivotal trial in up to 1,025 severe aortic stenosis patients. Boston Scientific expects the MiRus investment to be immaterial to its adjusted earnings per share in 2026.
Boston Scientific Corporation held its 2026 Annual Meeting of Stockholders in a virtual-only format, where stockholders approved key changes to the company’s charter and governance framework. The company’s Fourth Restated Certificate of Incorporation became effective after stockholders voted to remove supermajority voting provisions and to add exculpation protections for certain officers as permitted by Delaware law.
All 10 director nominees were elected for one-year terms, stockholders approved the advisory vote on compensation for named executive officers, and Ernst & Young LLP was ratified as the independent registered public accounting firm for the 2026 fiscal year. Stockholders also approved an amendment to the Employee Stock Purchase Plan to increase shares reserved, while two stockholder proposals related to giving shareholders the ability to call special meetings did not receive sufficient support.
Boston Scientific reported strong first quarter 2026 results, with net sales of $5.203 billion, up 11.6% year over year on a reported basis and 9.4% on an operational and organic basis. GAAP net income attributable to common stockholders rose to $1.341 billion, or $0.90 per diluted share, compared to $0.45 a year earlier, while adjusted EPS increased to $0.80 from $0.75, slightly above guidance.
Growth was broad-based, led by Cardiovascular net sales up 13.5% reported and 11.2% operational and organic, and MedSurg up 7.8% reported. By region, net sales grew 10.9% in the U.S., 14.7% in Asia-Pacific and 19.0% in Latin America and Canada on a reported basis.
For full year 2026, the company now expects net sales growth of 7.0–8.5% reported and 6.5–8.0% organic, and adjusted EPS of $3.34–$3.41. Second quarter 2026 guidance calls for reported net sales growth of 5.5–7.5%, organic growth of 5.0–7.0%, and adjusted EPS of $0.82–$0.84.
Boston Scientific filed an 8-K to share landmark clinical data for two cardiovascular therapies. The HI-PEITHO randomized trial in 544 patients with intermediate-risk pulmonary embolism showed the EKOS endovascular system plus anticoagulation was superior to anticoagulation alone on a composite endpoint (4.0% vs. 10.3%; 61% relative reduction), without intracranial bleeding through 30 days and with shorter hospital stays.
The CHAMPION-AF trial in 3,000 patients with non-valvular atrial fibrillation found the WATCHMAN FLX left atrial appendage closure device met all primary and secondary safety and efficacy endpoints versus leading blood thinners over 36 months, delivering markedly lower non-procedural bleeding (10.9% vs. 19.0%) and similar protection from stroke and cardiovascular death, with a 99% procedural success rate.
Boston Scientific arranged new bank financing to support its planned acquisition of Penumbra and refresh its liquidity facilities. The company entered into a $3.0 billion multi-year revolving credit agreement maturing on February 26, 2031, with interest tied to its credit rating and a required maximum leverage ratio.
It also put in place a $2.0 billion 364-day revolving credit facility and a $6.0 billion delayed draw term loan agreement, split into two 364-day tranches that can be drawn at the Penumbra acquisition closing. Tranche B borrowings must later be repaid or refinanced with proceeds from future equity or debt offerings, and both the revolvers and term loans carry ticking fees on undrawn commitments.
Following these new agreements, Boston Scientific terminated its prior revolving credit facility originally dated May 10, 2021, consolidating its bank financing under the new 2026 credit agreements.
Boston Scientific Corporation expanded its Board of Directors and significantly increased its share repurchase capacity. The board grew from ten to twelve members with the appointment of Catherine R. Smith, CFO of Starbucks, and Christophe P. Weber, president and CEO of Takeda Pharmaceutical, effective February 18, 2026.
Smith joins the Audit and Nominating and Governance Committees, while Weber joins the Executive Compensation and Human Resources Committee and the Risk, Science and Technology Committee as of February 23, 2026. Each will receive prorated non-employee director compensation, including a cash retainer of approximately $24,663 and an equity award valued at approximately $42,420, vesting at the end of their terms.
The board also approved an increase to the company’s existing common stock repurchase authorization by an additional $4.0 billion, bringing the total authorization to $5.0 billion, all of which remains available under the stock repurchase program.
Boston Scientific Corporation disclosed that director Yoshiaki Fujimori has informed the company he will not stand for re-election at the 2026 Annual Meeting of Stockholders. He has served on the Board since July 2016 and currently chairs the Risk, Science and Technology Committee.
Mr. Fujimori will continue as a director and in his committee roles until the 2026 Annual Meeting. The company states that his decision is not due to any disagreement with the company. The Board and its Nominating and Governance Committee will continue reviewing Board size and composition and may consider adding directors after his departure.
Boston Scientific Corporation furnished a Form 8-K to announce it issued a press release with financial results for the fourth quarter and full year ended December 31, 2025. The press release, dated February 4, 2026, is attached as Exhibit 99.1 and is furnished rather than filed for liability purposes.
Boston Scientific Corporation entered into a definitive Agreement and Plan of Merger to acquire Penumbra, Inc., which will become a wholly owned subsidiary. At closing, each Penumbra share can receive either $374.00 in cash or 3.8721 Boston Scientific shares, with a proration so that about 73.26% of shares receive cash consideration and 26.74% receive stock.
Completion of the merger depends on Penumbra stockholder approval, required antitrust and other regulatory clearances, effectiveness of a Form S-4 registration statement, NYSE listing of new Boston Scientific shares and other customary conditions, including no material adverse effects. The agreement includes reciprocal termination fees: Penumbra may owe $525,000,000 in certain superior-offer scenarios, while Boston Scientific may owe $900,000,000 if specified regulatory-related conditions prevent closing after Penumbra approval and other conditions are met.
Boston Scientific Corporation reported that it has signed a definitive agreement to acquire Penumbra, Inc. through a merger of a wholly owned Boston Scientific subsidiary with Penumbra. The transaction was announced in a joint press release and detailed in an investor presentation made available on the company’s website.
The acquisition is subject to closing conditions, including required regulatory approvals and clearances and other conditions outlined in the definitive agreement. Boston Scientific plans to file a Form S-4 registration statement containing a proxy statement/prospectus for Penumbra stockholders, who will receive detailed information before voting on the proposed transaction.
The filing emphasizes that statements about the expected financial and business impact and anticipated benefits of the transaction are forward-looking and subject to numerous risks, including regulatory outcomes, integration of Penumbra’s operations, and potential business disruptions following the announcement and closing.
Boston Scientific Corporation reported that its Board approved a new 2026 Annual Bonus Plan and two 2026 performance share programs for executive officers and other eligible employees. The cash bonus plan, covering the 2026 performance year, ties payouts to company-wide goals for global sales, adjusted earnings per share, operating income as a percent of sales, and corporate sustainability goals, with an aggregate bonus pool based on target bonuses and a distribution percentage between 0% and 150%. Individual awards can range from 0% to 225% of a participant’s target bonus through performance modifiers.
The Board also adopted the 2026 Relative Total Shareholder Return Performance Share Program, which measures total shareholder return against the S&P 500 Healthcare Index over a three-year period from January 1, 2026 to December 31, 2028, and the 2026 Organic Net Sales Growth Performance Share Program, which measures organic net sales growth versus the company’s financial plan over the same period. Under both programs, awards in the form of restricted stock units can range from 0% to 200% of target and vest only if performance and payment eligibility criteria are met, with clawback and recoupment policies applying to covered executive officers.
Boston Scientific (BSX) reported that director John E. Sununu will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders. He has served on the Board since 2009, is a member of the Audit Committee, and chairs the Nominating and Governance Committee. He will continue in these roles until the 2026 Annual Meeting.
The Company stated that Mr. Sununu’s decision is not the result of any disagreement with the Company. The Board and its Nominating and Governance Committee will continue to review the Board’s size and composition and evaluate whether adding directors following his departure is in the Company’s best interest.
Boston Scientific Corporation furnished an update on its financials, announcing it issued a press release with results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The disclosure under Item 2.02 is being furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated by reference into Securities Act or Exchange Act filings. The company also listed Exhibit 104 for the cover page Inline XBRL tags.
Boston Scientific Corporation announced that Jeffrey B. Mirviss, Executive Vice President and President, Peripheral Interventions, will retire effective December 1, 2025 and remain as a senior advisor through February 27, 2026. During the advisory period he will receive his current base salary of $705,000, prorated to the Retirement Date. The company expects to enter a Retirement Agreement providing payments and benefits materially consistent with its Executive Retirement Plan, 2025 Annual Bonus Plan and Long-Term Incentive Program and related equity awards.